IP Library Granted Patent US 9,717,742
Granted Patent B2
US 9,717,742 · App. 14/399,121 · Granted Aug 1, 2017

Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis

Inventors: Farhad Parhami (Los Angeles, CA); Michael E. Jung (Los Angeles, CA); Frank Stappenbeck (San Diego, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
A61K31/575A61K35/32A61K38/1841A61K38/1875A61K38/30A61K45/06C07J9/00C07J51/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,717,742
App. No.
14/399,121
Granted
Aug 1, 2017
Kind
B2
Abstract

This invention relates, e.g., to a synthetic compound, Oxy133, having the structure [Formula I] or a bioactive or pharmaceutical composition comprising Oxy133 and a pharmaceutically acceptable carrier. Methods are also disclosed for using the compound or bioactive or pharmaceutical composition to treat a variety of disorders, including e.g. bone disorders, obesity, cardiovascular disorders, and neurological disorders.

Claims (13)

1. A compound having the structure:

or a pharmaceutically acceptable salt or solvate thereof.

2. A composition, comprising a pharmaceutically acceptable carrier and a compound having the structure:

or a pharmaceutically acceptable salt or solvate thereof.

3. The composition of claim 2 , further comprising at least one additional agent, selected from the group consisting of parathyroid hormone, sodium fluoride, insulin-like growth factor I (ILGF-I), insulin-like growth factor II (ILGF-II), transforming growth factor beta (TGF-β), a cytochrome P450 inhibitor, an osteogenic prostanoid, BMP 2, BMP 4, BMP 7, BMP 14, and combinations thereof.

4. A method for treating a subject having a bone disorder, osteoporosis, or a bone fracture, comprising administering to the subject an effective amount of the composition of claim 2 .

5. The method of claim 4 , comprising administering to the subject the composition at a therapeutically effective dose in an effective dosage form at a selected interval to increase bone mass.

6. The method of claim 4 , comprising administering to the subject the composition at a therapeutically effective dose in an effective dosage form at a selected interval to ameliorate the symptoms of osteoporosis.

7. A method for treating a subject in need of an increase in osteomorphogenesis and/or osteoproliferation, comprising administering to the subject an effective amount of the composition of claim 2 .

8. A method for treating a subject to induce bone formation, comprising administering the composition of claim 2 in an effective dosage form at a selected interval to increase bone mass.

9. The method of claim 4 , wherein the composition is administered locally to a cell, tissue or organ in the subject.

10. An implant for use in a human or animal body comprising a substrate having a surface, wherein the surface or the insides of the implant comprises the composition of claim 2 in an amount sufficient to induce bone formation in the surrounding bone tissue.

11. The implant of claim 10 , wherein the substrate is formed into the shape of a pin, screw, plate, or prosthetic joint.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 22, 2015
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034793/0589 →
Continuity (2)
Provisional Application 61643746 · May 7, 2012
Related Publication 20150118277A1 · Apr 30, 2015